CTKB
NASDAQ · Life Sciences Tools & Services
Cytek Biosciences Inc
$5.89
+0.06 (+1.03%)
Financial Highlights (FY 2026)
Revenue
204.36M
Net Income
-67,488,083
Gross Margin
51.8%
Profit Margin
-33.0%
Rev Growth
+7.1%
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 51.8% | 51.8% | 58.3% | 58.3% |
| Operating Margin | -20.0% | -18.0% | 15.6% | 13.4% |
| Profit Margin | -33.0% | -31.4% | 11.9% | 11.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 204.36M | 190.81M | 285.65M | 250.25M |
| Gross Profit | 105.94M | 98.92M | 166.57M | 145.92M |
| Operating Income | -40,952,909 | -34,414,209 | 44.66M | 33.48M |
| Net Income | -67,488,083 | -56,712,674 | 33.87M | 27.85M |
| Gross Margin | 51.8% | 51.8% | 58.3% | 58.3% |
| Operating Margin | -20.0% | -18.0% | 15.6% | 13.4% |
| Profit Margin | -33.0% | -31.4% | 11.9% | 11.1% |
| Rev Growth | +7.1% | +7.1% | +23.4% | +11.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 7.81M | 7.81M | 185.65M | 183.29M |
| Total Equity | 390.59M | 390.59M | 348.72M | 320.85M |
| D/E Ratio | 0.02 | 0.02 | 0.53 | 0.57 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -33,271,145 | -29,512,220 | 45.08M | 40.37M |
| Free Cash Flow | — | — | 30.74M | 26.84M |